Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 11,177 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cohort study Clear all

Conditions: Residual Neuromuscular Blockade in Elderly Patients
Interventions: Age and incidence of residual neuromuscular blockade; Other
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Colorectal Neoplasms
Interventions: Botensilimab, Balstilimab; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Brooklyn, New York • Flushing, New York • New York, New York

Conditions: Fatty Liver
Interventions: possible liver biopsy and serum collection; Procedure
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: SARS-CoV-2
Interventions: mRNA-1283, mRNA-1273; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 6 Months to 11 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 13
States / cities: Ontario, California • Miami, Florida • Miami Lakes, Florida + 9 more

Conditions: HIV Infection, Liver Transplant
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Baltimore, Maryland • New York, New York

Conditions: OVARIAN CANCER
Interventions: Cobimetinib, Niraparib, Atezolizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 9
States / cities: Tucson, Arizona • La Jolla, California • Jacksonville, Florida + 6 more

Conditions: Extensive Stage Lung Small Cell Carcinoma, Extrapulmonary Small Cell Neuroendocrine Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma
Interventions: Berzosertib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Topotecan Hydrochloride; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 33
States / cities: Los Angeles, California • Newport Beach, California • Sacramento, California + 26 more

Conditions: Healthy Volunteers
Interventions: Esketamine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cypress, California

Conditions: Polypharmacy, Dementia, Multiple Chronic Conditions, Deprescribing, Mild Cognitive Impairment
Interventions: Educational Materials; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Reading, Pennsylvania

Conditions: HIV, PrEP
Interventions: PrEP awareness materials; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 16 Months to 40 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Bradycardia
Interventions: CARDIX-101A, CARDIX-101B, CARDIX-101C; Drug
Lead sponsor: Cardix Therapeutics LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Myelodysplastic Syndromes
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2052
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions: Biospecimen Collection, Follow-Up; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma, Pheochromocytoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: 90Y-DOTA-tyr3-OCTREOTIDE; Radiation
Lead sponsor: O'Dorisio, M S; Other
Eligibility: 2 Years to 25 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Depression, Mood, Sleep, Physical Activity
Interventions: Intern Health Study behavioral change mobile notification; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 1,047 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Interventions: TPI 287 2 mg/m2, TPI-287 20 mg/m2, Placebo, TPI-287 6.3 mg/m2; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 50 Years to 85 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Birmingham, Alabama • San Francisco, California

Conditions: Pregnancy, Obesity, Overweight
Interventions: No Intervention; Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 15 Years to 50 Years · Female only
Enrollment: 2,701 participants
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Princeton, New Jersey

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: Up to 6 Months
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 22
States / cities: St. Petersburg, Florida • Boise, Idaho • Chicago, Illinois + 19 more

Conditions: Osteoarthritis (OA) of the Hip
Interventions: Total hip arthroplasty via direct anterior approach (manual, non-robotic), Total hip arthroplasty via posterior approach (manual, non-robotic), Robotic-assisted total hip arthroplasty via posterior approach; Procedure
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Metairie, Louisiana • New Orleans, Louisiana

Conditions: Tri-specific Killer Engager, Solid Tumor, Advanced Solid Tumor
Interventions: GTB-5550; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Oropharyngeal Cancer, Squamous Cell Carcinoma of the Oropharynx
Interventions: Surgery, Chemoradiation, Observation, Post-operative radiation; Procedure · Combination Product · Other + 1 more
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Idiopathic Inflammatory Myositis (IIM), DERMATOMYOSITIS OR POLYMYOSITIS
Interventions: ULSC (1.5 x 10^8 cells/dose), Placebo (no cells); Biological
Lead sponsor: Restem, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Gainesville, Florida • Miami, Florida

Conditions: Papillary Thyroid Cancer, Pediatric Cancer, Differentiated Thyroid Cancer
Interventions: Whole body scan; Procedure
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 0 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2033
U.S. locations: 8
States / cities: San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more

Conditions: Influenza
Interventions: 2 mg/kg CR8020, 5 mg/kg CR8020, 15 mg/kg CR8020, 30 mg/kg CR8020, 50 mg/kg CR8020, Placebo; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

The Effect of Age on the Incidence of Postoperative Residual Neuromuscular Blockade

Combination Immunotherapy in Colorectal Cancer

Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Utilizing Ultrasound and Percutaneous Liver Biopsy

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age

Expanding HOPE Liver

A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

A Study to Assess the Pharmacokinetics of Intranasally Administered Esketamine in Healthy Japanese and Caucasian Volunteers

Shared Decision Making About Medication Use for People With Multiple Health Problems

Increasing PrEP Awareness and Demand Among Black Cisgender Women

An Exploratory Safety and Efficacy Clinical Study of CARDIX-101 for the Treatment of Chronic Bradycardia

Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies

Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Intern Health Study 2024

Safety Study of TPI-287 to Treat CBS and PSP

A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy

Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)

Gait After THA: Direct Anterior vs Manual Posterior vs Robotic Posterior

GTB-5550 in Advanced Solid Tumors

A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)

Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)

Targeted Therapy to Increase RAI Uptake in Metastatic DTC

Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses